BlackRock reports 15.6% stake in NeoGenomics
BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reports beneficial ownership of 20,358,331 shares, representing 15.6% of the outstanding common stock. Of these, 19,688,877 shares carry sole voting power and all 20,358,331 shares carry sole dispositive power.
The filing states that these holdings reflect securities beneficially owned, or deemed to be beneficially owned, by certain BlackRock business units, excluding other disaggregated units. It also notes that iShares Core S&P Small-Cap ETF has an interest in NeoGenomics common stock that is more than five percent of the total outstanding common stock.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of NeoGenomics (NEO) does BlackRock’s reported stake represent?
Does the BlackRock filing cover all BlackRock units’ holdings in NeoGenomics (NEO)?
Who signed the BlackRock beneficial ownership report for NeoGenomics (NEO)?
AI-generated analysis. How Rhea-AI works. Not financial advice.